Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

Rachel Husmann; John B Davies; Malik Ghannam; Brent Berry; Praful Kelkar

doi:10.1186/s12948-020-00119-4

Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

Clin Mol Allergy. 2020 Mar 12:18:3. doi: 10.1186/s12948-020-00119-4. eCollection 2020.

Authors

Rachel Husmann¹, John B Davies², Malik Ghannam³, Brent Berry³, Praful Kelkar⁴

Affiliations

¹ 1University of Minnesota, Minneapolis, MN USA.
² VitreoRetinal Surgery, PA, 7760 France Ave S, Suite 310, Minneapolis, MN USA.
³ 3Department of Neurology, University of Minnesota, MMC 295, 12-181 Phillips Wangensteen Building, 516 Delaware St. SE, Minneapolis, MN 55455 USA.
⁴ Minneapolis Clinic of Neurology, 4225 Golden Valley Road, Golden Valley, MN 55422 USA.

Abstract

Background: Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops.

Case presentation: A 38-year-old Caucasian female patient with history of relapsing-remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod.

Conclusion: FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up.

Keywords: Fingolimod; Macular edema; Multiple sclerosis; Nonsteroidal anti-inflammatory eye drops; Retina.

Publication types

Case Reports